{"analyses":[{"groupDescription":"For ICR Assessment","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0083","statisticalComment":"The p-value was from an unstratified 2-sided Fisher's exact test.","statisticalMethod":"Fisher Exact"},{"groupDescription":"For Investigator Assessment","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.1417","statisticalComment":"The p-value was from an unstratified 2-sided Fisher's exact test.","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.1","upperLimit":"30.5","value":"19.4"},{"groupId":"OG001","lowerLimit":"29.4","upperLimit":"45.7","value":"37.2"}]}],"title":"ICR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.1","upperLimit":"30.5","value":"19.4"},{"groupId":"OG001","lowerLimit":"21.7","upperLimit":"37.1","value":"29.0"}]}],"title":"Investigator"}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"description":"CRR was defined as the percentage of participants who achieved a complete response or complete metabolic response as their best overall response, as determined by ICR and investigator assessment. Responses were assessed from randomization until the data cutoff date, the start of a new anticancer therapy, or the crossover date for participants in the monotherapy arm who switched to combination therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Obinutuzumab 1000 milligrams (mg) intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6; and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG000","title":"Obinutuzumab"},{"description":"Zanubrutinib 160 mg twice a day orally with or without food and obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6, and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG001","title":"Zanubrutinib + Obinutuzumab"}],"paramType":"NUMBER","populationDescription":"ITT Analysis Set","reportingStatus":"POSTED","timeFrame":"From first dose to primary analysis data cutoff (08OCT2021) start of a new anticancer therapy, or the crossover date, whichever came first. Median follow-up was 12.45 months.","title":"Complete Response Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}